Summary
Paion AG (PAION) is a pharmaceutical company that develops anesthesia products and drugs for hospital based treatment. Its product portfolio includes Remimazolam, Glial Growth Factor 2 (GGF2) and M6G. Its M6G an active metabolite of morphine is beng developed for the treatment of post-operative pain. PAION also offers Phase-III clinical trials for the cure of anesthesia and procedural sedation, and Phase-II clinical trials for ICU sedation. The company’s products find application in the therapeutic areas of stroke, thrombotic diseases, blood vessel related diseases and central nervous system disorders. It has its operations in the UK; New Jersey, the US; and Germany. PAION is headquartered in Aachen, Germany.
Paion AG (PA8) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Paion AG, Medical Devices Deals, 2010 to YTD 2016 9
Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Paion AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Paion Raises US$4.8 Million In Venture Financing 11
Licensing Agreements 12
Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 12
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 13
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 14
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 16
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18
Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20
Paion Enters Into Option Licensing Agreement With Yichang Humanwell Pharma For Remimazolam 22
Lundbeck Expands Licensing Agreement With PAION For Desoteplase 24
Equity Offering 26
Paion Raises USD5.4 Million in Private Placement of Shares 26
Paion Raises USD61.3 Million in Rights Offering of Shares 27
Paion Raises USD1.4 Million in Private Placement of Shares 28
Paion Completes Private Placement of Shares for USD8.5 Million 30
Paion Completes Private Placement Of Shares For US$8.4 Million 32
Paion Completes Rights Offering of Shares for USD6.86 Million 33
Paion Completes Private Placement Of Shares For US$19 Million 34
Asset Transactions 35
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 35
Paion AG - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Paion AG, Pharmaceuticals & Healthcare, Key Facts, 2014 1
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Paion AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Paion AG, Deals By Therapy Area, 2010 to YTD 2016 8
Paion AG, Medical Devices Deals, 2010 to YTD 2016 9
Paion AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Paion Raises US$4.8 Million In Venture Financing 11
Paion Enters into Licensing Agreement with Yichang Humanwell for M6G 12
Paion Exercises Option for Licensing Agreement with PendoPharm for Remimazolam 13
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 14
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 16
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 18
Paion Exercises Option for Licensing Agreement with Hana Pharma for Remimazolam 20
Paion Enters Into Option Licensing Agreement With Yichang Humanwell Pharma For Remimazolam 22
Lundbeck Expands Licensing Agreement With PAION For Desoteplase 24
Paion Raises USD5.4 Million in Private Placement of Shares 26
Paion Raises USD61.3 Million in Rights Offering of Shares 27
Paion Raises USD1.4 Million in Private Placement of Shares 28
Paion Completes Private Placement of Shares for USD8.5 Million 30
Paion Completes Private Placement Of Shares For US$8.4 Million 32
Paion Completes Rights Offering of Shares for USD6.86 Million 33
Paion Completes Private Placement Of Shares For US$19 Million 34
Lundbeck Acquires Desmoteplase, Ischaemic Stroke Drug From Paion For US$27 Million 35
Paion AG, Key Competitors 37
Paion AG, Key Employees 38
Paion AG, Subsidiaries 39
List of Figures
Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Paion AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Paion AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Paion AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Paion AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Paion AG, Medical Devices Deals, 2010 to YTD 2016 9